The company’s quarterly gross profits were $23.1 million, up 33 percent from last year. Operating costs also increased by 32 percent to $24 million over the past three months.
The company also attributes the loss in part to $4.7 million in noncash expenses for the revaluation of warrants leading up to the IPO.
LDR’s primary products are non-fusion devices for cervical and lumbar spine. In September, the company announced its proposal and plans for an IPO.
More Articles on Devices:
MAKO Surgical Suffers $21.3M Net Loss in Q3, Decreased RIO Sales
Biomet to Distribute Titan Spine Fusion Devices in Germany, Per Agreement
Going Global: How K2M Grew Internationally & Where the Spine Device Market is Headed
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
